Rollins (NYSE:ROL) reported quarterly earnings of $0.20 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $714.00 million which beat the analyst consensus estimate of $686.33 million by 4.03 percent. This is a 11.88 percent increase over sales of $638.20 million the same period last year.
Sutro Biopharma’s Ovarian Cancer Candidate Fast Tracked In US
The FDA has granted Fast Track designation to Sutro Biopharma Inc’s (NASDAQ:STRO) STRO-002 for ovarian cancer. The designation covers platinum-resistant epithelial ovarian,…
